• Login
    View Item 
    •   Home
    • 1 Published Research and Commentary
    • Ebola
    • View Item
    •   Home
    • 1 Published Research and Commentary
    • Ebola
    • View Item
    Mar 02, 2021
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of MSFTitleAuthorsSubjectsPublisherJournalThis CollectionTitleAuthorsSubjectsPublisherJournal

    Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Cross et al 2020 Prior vaccination ...
    Size:
    2.688Mb
    Format:
    PDF
    Download
    Authors
    Cross, RW
    Bornholdt, ZA
    Prasad, AN
    Geisbert, JB
    Borisevich, V
    Agans, KN
    Deer, DJ
    Melody, K
    Fenton, KA
    Feldmann, H
    Sprecher, A
    Zeitlin, L
    Geisbert, TW
    Show allShow less
    Issue Date
    2020-07-27
    Submitted date
    2020-10-06
    
    Metadata
    Show full item record
    Journal
    Nature Communications
    Abstract
    A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic. Additionally, chimeric and human monoclonal antibodies (mAb) against the EBOV GP have shown promise in animals and humans when administered therapeutically. Uncertainty exists regarding the efficacy of postexposure antibody treatments in the event of a known exposure of a recent rVSV-ZEBOV vaccinee. Here, we model a worst-case scenario using rhesus monkeys vaccinated or unvaccinated with the rVSV-ZEBOV vaccine. We demonstrate that animals challenged with a uniformly lethal dose of EBOV one day following vaccination, and then treated with the anti-EBOV GP mAb MIL77 starting 3 days postexposure show no evidence of clinical illness and survive challenge. In contrast, animals receiving only vaccination or only mAb-based therapy become ill, with decreased survival compared to animals vaccinated and subsequently treated with MIL77. These results suggest that rVSV-ZEBOV augments immunotherapy.
    Publisher
    Nature Research
    URI
    http://hdl.handle.net/10144/619732
    Language
    en
    Collections
    Ebola

    entitlement

     
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.